Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 7,520 articles

Articles by Daniel Marsh

AI Rally Drives S&P 500 and Nasdaq to New Highs Despite Oil Price Surge
Markets

AI Rally Drives S&P 500 and Nasdaq to New Highs Despite Oil Price Surge

The S&P 500 and Nasdaq closed at record highs Friday, driven by AI chip stocks and a better-than-expected April jobs report, even as oil prices climbed. Nvidia, Micron, and SanDisk posted strong gains.

NVDA MU SNDK AMD INTC CRM SNOW CRWD CLSK ENPH
Moderna Jumps 10% on Hantavirus Vaccine Push as Cruise Ship Outbreak Revives mRNA Hopes
Markets

Moderna Jumps 10% on Hantavirus Vaccine Push as Cruise Ship Outbreak Revives mRNA Hopes

Moderna shares rose 10% on Friday after the company revealed early-stage work on a hantavirus vaccine, spurred by a deadly Andes virus outbreak on the MV Hondius cruise ship.

MRNA GSK
Wynn Resorts Shares Slide on UAE Delay and $900M Macau Expansion
Markets

Wynn Resorts Shares Slide on UAE Delay and $900M Macau Expansion

Wynn Resorts stock dropped 6.7% Friday despite beating Q1 profit estimates, as a delayed UAE opening and a $900M+ Macau expansion raised capital concerns.

WYNN LVS MGM
Arbor Realty Trust Plunges After Dividend Cut and Weak Q1 Results
Markets

Arbor Realty Trust Plunges After Dividend Cut and Weak Q1 Results

Arbor Realty Trust cut its dividend to $0.17 and reported Q1 net income of just $629,000, sending shares down 11% as investors focus on troubled loans.

Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Markets

Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift

Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.

NVAX PFE SNY MRNA
POET Technologies Stock Rebounds Amid Securities Lawsuit and Marvell Fallout
Markets

POET Technologies Stock Rebounds Amid Securities Lawsuit and Marvell Fallout

POET Technologies shares rebounded 14.5% to $10.97 on Friday, even as a securities lawsuit over tax disclosures and cancelled Celestial AI orders moves forward with a June 29 lead plaintiff deadline.

POET MRVL AVGO NVDA
Traws Pharma Soars on Hantavirus Push After Cruise Fatalities
Markets

Traws Pharma Soars on Hantavirus Push After Cruise Fatalities

Traws Pharma shares surged over 21% after the biotech said it would advance hantavirus drug candidates following a fatal cruise ship outbreak. The company has no approved treatments and recently raised $10 million.

TRAW
Eos Energy Shares Surge 22% Ahead of Earnings on AI Data Center Deal
Markets

Eos Energy Shares Surge 22% Ahead of Earnings on AI Data Center Deal

Eos Energy shares surged 22% to $7.75 ahead of its May 13 earnings report, fueled by a joint development deal with TURBINE-X Energy for AI data center storage. Investors eye manufacturing rebound and legal hurdles.

EOSE
S&P 500 and Nasdaq Scale New Peaks on Robust Jobs Data
Markets

S&P 500 and Nasdaq Scale New Peaks on Robust Jobs Data

The S&P 500 and Nasdaq reached all-time highs midday Friday, buoyed by stronger-than-expected April jobs data and gains in Nvidia and Apple.

AAPL NVDA AKAM MNST
Dow Steady as Strong Jobs Data Dims Rate Cut Hopes, Tech Surges
Markets

Dow Steady as Strong Jobs Data Dims Rate Cut Hopes, Tech Surges

The Dow Jones slipped 0.03% on Friday as strong April jobs data reduced hopes for a Federal Reserve rate cut, while tech stocks like Nvidia and Apple surged over 2%.

AAPL NVDA CSCO AMAT WMT
Xanadu Quantum Shares Slide as New Leveraged ETF Launches and 294M Share Filing Looms
Markets

Xanadu Quantum Shares Slide as New Leveraged ETF Launches and 294M Share Filing Looms

Xanadu Quantum stock dropped 6.16% to $16.31 amid a 294 million-share filing and the launch of a 2x leveraged ETF. Q1 results are due May 14.

GD Culture Group Weighs $10.75/Share Bid as Stock Trades at $0.16
Markets

GD Culture Group Weighs $10.75/Share Bid as Stock Trades at $0.16

GD Culture Group is reviewing a $10.75/share buyout bid from two investors, but with shares at $0.16 and financing unsecured, the deal faces significant hurdles.

GDC